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Abstract: Several fold increase in allergic diseases in developed,
high-income countries during recent decades is attributed to envi-
ronmental changes such as urbanization with improved hygiene.
This, together with conquering severe bacterial infections during
childhood, has reduced the microbial stimulation of the developing
immune system of infants. Studies on the pathogenesis of allergy
both in man and experimental animal have shown the importance of
commensal bacteria in the gastrointestinal tract in stimulating and
directing the immune system. The interest in modulating commensal
bacterial flora with probiotics to prevent and treat allergy has
multiplied in recent years.
In the present review we report results on randomized, controlled
studies in which childhood atopic eczema was treated or which
aimed to prevent development of allergy during childhood.
Nine studies with 639 patients have looked at the effect of
probiotics in treatment of eczema. While 3 studied showed no effect,
other studies suggested a moderate benefit of the use of probiotics on
the severity of eczema. Studies suggested that the effect may be seen
particularly in patients with food allergy and/or sensitization.
Nine studies have reported on the prevention of allergy on 6 study
population with altogether 1989 high risk infants. While the early study
reporting the development of allergy at ages 2, 4 and 7 years showed a
marked reduction of eczema in 77 treated infants, later studies have
failed to show similar success. Two studies showed no effect. In the
largest study with more than 900 children at age 2 atopic eczema was
reduced by 20%, but at age 5 positive effect was present in only the
subgroup of children who had born by cesarean section. None of studies
has reported adverse effects of probiotics in infants.
Result in both treatment and prevention studies are quite vari-
able, the major reason being the use of different strains of probiotic
bacteria and varying types of intervention. Even if the results are
encouraging, we need a stronger effect. This may be reached by
finding new strains of probiotics affecting stronger stimulation of
immune system, together with longer lasting and varying treatment
schedules. However, safety issues have to be observed.
Key Words: probiotics, prevention of allergic diseases, treatment
of allergic diseases, atopic eczema
(WAO Journal 2009; 2:69–76)
INTRODUCTION
The marked increase in the prevalence of allergic diseasesduring the past 50 years is associated with the decrease of
life-threatening infections during childhood and the postin-
dustrial changes in lifestyle, characterized by a high standard
of hygiene and reduced exposure to microbes in daily envi-
ronments.1,2 Gerrard et al already proposed in the 1970s that
this increase is the price we have to pay for better survival of
children, although the “hygiene hypothesis” was formulated
by Strachan, who found fewer allergies in families with a
greater number of children. This led him to postulate that
infections protected them from allergy.3,4 Epidemiologic
studies show that persons having had infections of the gas-
trointestinal tract, like hepatitis A, have lower prevalence of
allergies,5 whereas some other types of infections, for exam-
ple, measles, may increase the risk for allergy.6
Other types of stimulation of the mucosal immune
system by bacterial antigens, particularly by bacterial endo-
toxins and lipopolysaccharides, have markedly affected the
appearance of allergic diseases during childhood. Increased
endotoxin exposure has been associated with living on a farm
and results in reduced risk for atopy and for asthma.7,8
Exposure to unpasteurized farm milk independently (without
exposure to the stables) was associated with less atopy and
respiratory allergies.9 Children in families with anthroposo-
phist lifestyle have fewer allergies than other children living
in the same area; they use fewer antibiotics, vaccinations are
more seldom taken, and they consume fermented foods,
plentiful in lactic acid bacteria; only the use of organic or
biodynamic fermented foods are significantly associated with
the reduction of allergies.10
The most powerful, direct stimulant of our largest
immune organ, gut-associated lymphoid tissue, is the large
and active gut microbiota, with up to 100 trillion microbes
weighing more than 1 kg. They occupy all available niches
from the intestinal lumen to crypts and epithelial-cell surfaces
with an increasing gradient from stomach to colon.11,12 The
gut microbiota have huge metabolic activity and through
fermentation of their main substrates, undigested dietary
carbohydrates, produce short-chain fatty acids (acetate, pro-
pionate, and butyrate), carbon dioxide, and molecular hydro-
gen, salvaging some of the energy of these products for the
host.13 The sterile gut of the newborn is gradually colonized
by environmental bacteria. Vaginally born infants acquire the
microbiota having the strongest association with the mother’s
colon.14 Cesarean section delays fecal colonization by bi-
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fidobacteria, lactobacilli, and Bacteroides15,16 and may affect
composition of the microbiota up to age 7.17 Later, the type of
feeding influences the initial colonization.16 Human milk
oligosaccharides promote the growth and activity of bi-
fidobacteria and lactobacilli,18 which more abundantly colo-
nize breastfed than formula-fed infants.19 In unhygienic en-
vironments, the gut flora has high diversity and a high
turnover rate.20 Such conditions, related to decreased risk for
allergies, provide continuous exposure to an extensive array
of bacteria in drinking water and in the soil and constantly
stimulate the immune system.21
Several observations indicate that alterations in gut
microbiota precede the development of allergies. In 2 coun-
tries with either low (Estonia) or high (Sweden) prevalence of
allergy, healthy infants had differences in their microbiota.22
In prospective studies, early fecal samples of infants who go
on to develop allergies compared to those who remain healthy
grow less enterococci, bifidobacteria, and Bacteroides and
more clostridia and staphylococci.23 In a Finnish study of
genetically allergy-prone infants, early gut microbiota also
differed between those who went on to develop atopy and
those nonsensitized by age 1.24 In the feces of 5-year-old
Esthonian children, those with allergic diseases had less
commonly bifidobacteria than those without allergy, whereas
clostridia was more common in allergic children. The counts
of clostridia correlated with the level of serum IgE in allergic
children.25 Japanese infants developing early allergy had
different Bifidobacterium species compared to those of non-
allergic infants; they particularly had the adult type Bi-
fidobacterium catenulatum as has been described earlier in
another population.26
In the experimental animal model for food allergy, the
gut microbiota and its stimulatory action of innate immune
system by toll-like receptors (TLR), particularly TLR4, is of
paramount importance. Food tolerance does not develop in
germ-free mice, but is inducible after colonization of the
intestine.27 Mice susceptible to food allergy have a mutation
in TLR4, blocking its signaling.28 The deficiency of TLR4
influenced food sensitization and anaphylaxis to bovine
-lactoglobulin depending on the genetic background of the
mice.29
Altering the intestinal microbiota of an individual is a
tempting possibility to treat allergic symptoms and to prevent
development of allergies. Probiotic bacteria are “live micro-
organisms, which administered in adequate amounts confer
health benefits on the host” (Organization FAO 2002,
http://www.who.int/foodsafety/publications/fs_management/
probiotics2/en). They are a heterogeneous group of bacteria
with specific biological activities. Lactobacilli, bifidobacteria,
and streptococci are strains most commonly selected from
among human microbiota or dairy-product starters. Lactoba-
cilli, bifidobacteria, and propionibacteria belong to the lactic
acid bacteria group. They are fermentative Gram-positive
bacteria and produce lactic acid as their main fermentation
product. Lactobacilli are naturally present in human and
animal intestines and in fermented vegetables or dairy prod-
ucts. Lactobacillus rhamnosus GG (LGG), which was iso-
lated from human feces by Gorbach and Goldin, is the most
studied probiotic.14 Bifidobacteria are natural residents of the
human intestine, but propionibacteria occur naturally in dairy
products and traditionally serve as cheese starters. Prebiotics
are indigestible substances that benefit the host by selectively
stimulating the growth or the activity or both of a limited
number of bacterial strains established in the gut, thereby
having impact on allergies. The term “synbiotics” means a
combination of these factors.
TREATMENT OF ALLERGIC DISEASES
Majamaa and Isolauri30 studied LGG in the treatment
of eczema in 42 Finnish infants referred to a hospital for
suspected cow’s milk allergy in 1997. LGG was given open-
label for 1 month to 11 breast-feeding mothers or randomized
directly to 15 infants receiving extensively hydrolyzed for-
mula. In the control group to the latter, 16 infants received
only extensively hydrolyzed formula. In the final analysis, 37
of 42 infants undergoing a positive cow’s milk challenge after
the intervention were included. In these 37, the SCORAD
index31 improved significantly in the 13 formula-fed infants
receiving L. rhamnosus GG and in the 10 breast-fed infants
whose mothers received LGG. In the 14 control infants, the
index remained unchanged. However, at 2 months the mod-
erate-to-severe eczema became mild in both study groups.
(Table 1). The other Isolauri’s study included 27 infants
suffering from eczema during exclusive breast-feeding. Of
them, 9 were weaned onto extensively hydrolyzed formula, 9
infants onto the same formula with added LGG, and 9 infants
received the formula with added Bifidobacterium lactis Bb12.
After 2 months, in infants receiving the probiotic-containing
formulas, severity of eczema decreased significantly, whereas
the placebo group showed no improvement; 6 months later,
eczema had improved in all infants, with no difference
between study groups (Table 1).32
Rosenfedlt et al33 studied 43 children aged 1 to 13 years
with eczema, in a double-blind, placebo-controlled crossover
setting with a combination of 2 strains of bacteria (Table 1).
A significantly greater proportion (56%) of patients experi-
enced improvement after active treatment than after placebo
(15%). A greater decrease in SCORAD index appeared
among patients with atopic constitution after probiotic treat-
ment than after placebo. Lactobacillus fermentum given for 2
months to 56 Australian 6- to 18-month-old infants, 71% of
whom were sensitized, ameliorated their moderate-to-severe
eczema.34
Our own study entailed 230 infants in a randomized
controlled trial where LGG, a mixture of 4 probiotics, or
placebo was given for 1 month to infants with eczema. Half
of them were diagnosed by a double-blind, placebo-con-
trolled food challenge to have cow’s milk allergy (CMA).35
Although probiotics had no additional therapeutic effect on
healing of eczema in infants with or without CMA, in
subgroup analysis, LGG compared to placebo was superior in
infants with IgE-associated eczema (P  0.027).35 The great-
est effect of LGG was among patients with severe eczema
(SCORAD  30) and IgE positivity. Colonization of the
supplemented probiotics was successful when analyzed from
fecal samples.
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No effect of probiotics was observed in 42 Dutch
infants aged 1 to 5 months, given either LGG or another L.
rhamnosus strain for 3 months in hydrolyzed formula com-
pared to infants given hydrolyzed formula alone for ecze-
ma.36 Two German studies also showed negative results: in a
study on 102 infants, treatment with LGG for 3 months
resulted in the same rate of improvement of eczema as that
with placebo in the whole study group and in those with
sensitization.37 In the other study, 53 children with eczema,
aged 1 to 55 months, were given either LGG or placebo for
2 months; no difference was observed in the clinical course of
the groups.38 Three months’ treatment of young children
(median age 4 years) with a combination of L. rhamnosus and
B. lactis improved eczema in the subgroup sensitized to food,
whereas in the whole study group there was no difference.39
The effect was transient.
PREVENTION OF ATOPIC DISEASE
The first study on the possibility to prevent allergy in
high-risk infants comprised 159 mothers from allergy-risk
families who were randomized to receive LGG 4 weeks
before delivery, and after delivery the breast-feeding mothers
continued LGG but only bottle-fed infants received LGG
directly (57%) until 6 months of age. At age 2, the prevalence
of atopic eczema in the LGG group was 23% and in the
placebo group 46%; the relative risk for developing eczema
was significantly lower in the LGG group (Table 2).40 At age
4, 107 children came to a follow-up examination: in the LGG
group eczema was diagnosed in 26% and in the placebo
group 44%41; relative risk for eczema at age 4 remained
significantly reduced (Table 2). An equal number of children
in each group had respiratory allergic symptoms, and preva-
lence of sensitization was similar. Seventy-three percent of
the children completed the 7-year follow-up. The prevalence
of eczema remained significantly lower in the LGG group,
43% versus 66%; positive skin prick tests were detected in
32% of the children with no difference between the groups.
The incidence of allergic airway diseases was low and similar
in the study groups.42 Kopp et al simulated the above study by
giving LGG or placebo to 105 pregnant women carrying
high-risk babies for 4 to 6 weeks before delivery and then to
their infants for 6 months. They found a similar incidence of
eczema (28% vs 27%) and of sensitization rates at age 2, but
LGG was associated with an increased rate of recurrent
wheezing episodes (26% vs 9%).43
In another randomized trial, Lactobacillus acidophilus
(LAVRI-A1) or placebo was given only postnatally to 178
newborns of allergic women until 6 months of age.44 At 1
year, no differences in the rates of eczema in the probiotic
(43%) and placebo (39%) groups were found. Unexpectedly,
increased frequency of sensitization was found in the probi-
otic group, 40%, compared to the placebo (24%) group. The
proportion of children with atopic eczema having a positive
skin prick test was greater in the probiotic group, 23/88
(26%), than in the placebo group, 12/86 (14%), P  0.045.
Abrahamsson et al gave either Lactobacillus reuteri or
placebo daily to pregnant mothers of high-risk families from
36 weeks of gestation until delivery and to their babies from
birth until 1 year of age.45 In the 188 infants at the 2-year
follow-up, the cumulative incidence of eczema was 35% in
both groups, but during the second year of life, atopic eczema
was less common in the probiotic group (8%) than in the
placebo group (20%). The cumulative incidence of sensitiza-
tion as measured by serum antigen-specific IgE against egg
white and cow’s milk or in a skin prick test against egg, milk,
cat, birch, or timothy tended to be lower in the probiotic
group (18% vs 29%); when infants with maternal allergy
were compared, the difference was significant (14% vs 31%,
P  0.02).
Wickens et al46 randomized 512 mothers of high-risk
infants to receive either L. rhamnosus HN001 or Bifidobac-
terium animalis subspecies or placebo from 35 weeks of
gestation; to the infants the treatment was continued until age
2. L. rhamnosus significantly reduced risk of eczema com-
pared with placebo, but the other strain bifidobacteria had no
effect. IgE-associated eczema was reduced in the same way,
but sensitization rates were similar by age 2.
We randomized for a double-blind placebo-controlled
trial 1223 pregnant women carrying fetuses at increased risk
for allergies.47 These mothers used a mixture of 4 probiotic
bacteria, or a placebo, from their 36th week of gestation.
Their infants received the same probiotics plus prebiotic
galacto-oligosaccharides for 6 months. In the probiotic group
compared to the placebo group, fecal counts for all lactoba-
cilli and bifidobacteria were significantly higher than those in
the controls at age 6 months. Probiotic strains were also
detected more frequently, recovery of the probiotics in the
feces was transient, and no differences in the colonization
patterns occurred at 2 years of age.
A total of 925 infants participated in the 2-year follow-
up. The cumulative incidence of any allergic disease (food
allergy, eczema, asthma, and allergic rhinitis) did not differ
significantly between the probiotic (32%) and the placebo
(35%) groups. However, probiotics compared to placebo
tended to reduce all atopic (IgE-associated, assessed by skin
prick test and or specific IgE 0.7 kU/L)) diseases (Table 2).
Eczema, which constituted 88% of all allergic diseases by age
2, occurred less frequently in the probiotic group (26%) than
in the placebo group (32%). The preventive effect was more
pronounced against atopic (IgE-associated) eczema, its inci-
dence in the probiotic group (12%) was significantly lower
than that in the placebo group (18%). Sensitization, however,
was not affected.
At age 5, 891 (88%) of the group attended the follow-up
examination.48 The frequencies of allergic and IgE-associated
allergic disease and sensitization in the probiotic and placebo
groups were similar: 52.6% versus 54.9% and 29.5% versus
26.6% and 41.3% in both. There was also no difference in the
frequencies of eczema (39.3% vs 43.3%), atopic eczema (24.0%
vs 25.1%), allergic rhinitis (20.7% vs 19.1%), nor asthma
(13.0% vs 14.1%) between the groups. However, caesarean-
delivered children receiving probiotics were sensitized less fre-
quently; the difference in prevalence of positive IgE antibodies
to food allergens was significant, they had less IgE-associated
allergic disease, and the cumulative prevalence for atopic ec-
zema was significantly reduced (15.7% vs 30.4%).48
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SAFETY OF PROBIOTIC TREATMENT
No serious adverse effect has been reported in the
studies using probiotics in infants and children to treat or
prevent allergies. In our intervention, the early adverse symp-
toms that could be caused by probiotics (abdominal pains,
excessive crying, and constipation) were equally common in
the probiotic and placebo group.49 The growth of the children
in the groups was exactly the same. The concentrations of
hemoglobin at ages 2 and 5 were the same, although at age 6
months those receiving probiotics had signs of iron deficiency.50
Infants on probiotics in fact showed some favorable
effects of the treatment. They had had less respiratory infec-
tion at age 6 to 24 months and had received less frequently
antibiotics from birth to 6 month.49 At age 6 months they
more frequently had protective titers against Hemophilus
influenzae B than those on placebo.51 From a mean age of 7
months, 118 healthy infants consumed a formula supple-
mented with B. lactis and Streptococcus thermophilus for 7
months. It was well tolerated and safe and normal growth was
observed.52
MODE OF ACTION OF PROBIOTICS
A large number of studies describe immunologic ef-
fects of probiotics on human cells or on experimental ani-
mals. However, in our opinion the majority gives no infor-
mation relevant to the human in vivo situation. Effects of
probiotic bacteria on human cells do not reflect conditions in
the intestine, where contact with bacteria takes place only for
epithelial cells and for extensions of dendritic cells.53
Majamaa and Isolauri inferred that probiotics reduce
the inflammation in the intestine.30 Inflammatory cytokine,
tumor necrosis factor- content was reduced in the fecal
extracts of patients receiving LGG, whereas no change took
place in the extracts from controls.30 In a later study,32
concentrations of urinary eosinophilic protein-x became
lower in 2 groups receiving probiotic treatment and was
unchanged in controls.
It has been suggested that probiotics act by reducing the
permeability of the intestine.54 In their double-blind placebo-
controlled crossover study, probiotic treatment resulted in a
lower ratio of lactulose/mannitol in the urine.54 We however
did not find any change in intestinal permeability during the
treatment of infants with eczema with either LGG or a
combination of probiotic strains.55
We found no difference in the tumor necrosis factor-
content in the feces of patients receiving either probiotics or
placebo.56 However, LGG treatment resulted in a greater
increase in concentration of IgA after a positive CM chal-
lenge test of IgE-mediated cow’s milk allergic infants than
that in controls.57 In the prevention study, we discovered that
high fecal IgA concentrations at age 6 months protected the
infant/child from atopic (IgE-associated) diseases by age 2
years. Probiotics led to increased concentrations of inflam-
matory markers, fecal 1-antitrypsin and calprotectin, and
tended to augment fecal IgA concentrations.58 We therefore
infer that in the intestine, probiotics may enhance both in-
flammation and immune defense of the gut.
When we studied the ability of peripheral blood mono-
nuclear cells to secrete various cytokines before and after
treatment with probiotics and placebo, we found the secretion
of interferon- (IFN-) to be significantly lower in IgE-
mediated cow’s milk allergic infants than in infants without
CMA.59 Treatment with LGG resulted in a significant in-
crease in the ability of peripheral blood mononuclear cells to
secrete IFN- among patients with atopic eczema, the same
group which benefited clinically from the treatment.59 The
same increase was observed for IFN- responses to mitogens
and staphylococcal enterotoxin B in infants with eczema
given L. fermentum VRI 003.60 Interestingly, in our study, the
mixture of probiotics acted differently from LGG: Secretion
of IL-4 increased significantly in infants with CMA during
the intervention with the mixture, whereas LGG did not effect
this cytokine secretion.59
Both in the treatment and prevention study we found
evidence that probiotics induce low-grade inflammation,
which probably is associated with the healing/protective ac-
tions of probiotics. During treatment of eczema with LGG,
we found a significant increase in blood concentration of
C-reactive protein (CRP) in infants having had a favorable
clinical effect, in those with IgE-associated eczema. The
LGG treatment affected the serum concentration of IL-6,
which was significantly increased in the group with increased
CRP. IL-6 may thus induce the secretion of CRP in the liver.
The effect of the mixture of probiotics differed; it had no
affect on IL-6 levels, but was associated with a significant
increase in IL-10.56 In infants with high risk of allergy, the
mixture of probiotics was associated with an increase of CRP
at age 6 months; they also had higher IL-10 levels. Further-
more, they had higher levels of serum IgA and IgE levels than
those given placebo.61 We, therefore, infer that probiotics
induce a low-grade inflammation characterized as an increase
in CRP, total IgA, total IgE, and IL-10 levels. These changes
closely resemble those seen in helminth infections and are
associated with induction of regulatory mechanisms and re-
duced incidence of allergy.62
Commensal microbiota and their recognition by TLRs
are important in host defense and directing specific immune
responses of the gut and in development of food allergy in
experimental animals.63,64 Probiotic strains have the ability to
adhere to gut epithelial cells, which may express TLRs65 and
stimulate these cells to produce cytokines. Extension of
dendritic cells samples the intestinal lumen and functions in
the development of immune responses in the gut.53 These
cells may be stimulated by probiotic bacteria. In vitro, iso-
lated myeloid dendritic cells express TLR-2 and may be
stimulated by LGG to express inflammatory cytokines.66 We
thus infer that stimulation of innate immunity may be the
basis of the observed inflammatory signs and beneficial
clinical effects.
CONCLUSIONS
Studies with probiotics to treat and prevent allergy
show promising, although highly variable, results as also
discussed in 3 recent reviews.67-69 Clearly, the major variable
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among the studies is the use of different bacterial strains; only
results using the same strain and similar set-up are comparable.
We believe that the concept is valid: the intestine of a
newborn and also an older infant may be transiently colo-
nized with bacteria given orally. These bacteria have an effect
on the immune system of the recipient and also have clinical
effects. Probiotics have been effective in the treatment of
eczema in infants, although the results are modest. In pre-
vention, we saw the longest lasting results in the subgroup of
children born by caesarean section. In that event we can
introduce the probiotic to the intestine with low counts of
bacteria and higher counts of given strains in the intestine
may be reached. However, in all instances the colonization by
given strains have been transient.
In attempts to prevent allergy in high-risk infants the
results suggest that intervention should start with the mother
during pregnancy to make sure that the birth canal of the
mother is colonized by probiotics.
Whether both infants and their mothers should continue
probiotics after birth is an open question; giving probiotics
directly to infants is proven to result in colonization.
Finding the most efficient strain of probiotics is a big
challenge. We do not believe in vitro studies can simulate
conditions in vivo, although some qualities of probiotic
bacteria may be found in those studies. Experimental animals
have gut microbial flora, which for example in mice has less
than 50% DNA identity with the human microbiota. There-
fore, much caution is needed to apply results from experi-
mental animal studies. Even in human experiments, we do not
know what type of immune reaction should result from the
ingestion of probiotics to prove their effect in allergy treat-
ment and prevention. Furthermore, the immune response to
probiotics may be genetically determined and differ in per-
sons with and without allergy proneness.
For more efficient and long-lasting effects, we need
more potent and longer lasting stimulation of the mucosal
immune system. Maybe the intervention has to continue
lifelong; its type has to be changed or added up at intervals.
Challenges to find a safe and efficient intervention for the
primary prevention of allergies are great, but first steps have
been taken.
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